Late-Stage Sickle Cell Disease Study Splits on Main Goals

(MedPage Today) -- The thalassemia drug mitapivat (Aqvesme) significantly improved hemoglobin response in patients with sickle cell disease but failed to top placebo when it came to reducing pain crises in a phase III trial that aims to support...